[1]
Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer treatment and research. 2009:152():3-13. doi: 10.1007/978-1-4419-0284-9_1. Epub
[PubMed PMID: 20213383]
[2]
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009 Apr 1:115(7):1531-43. doi: 10.1002/cncr.24121. Epub
[PubMed PMID: 19197972]
[3]
Ratnagiri R, Garg V, Chaturvedi R. Extra osseous osteosarcoma of the retroperitoneum: an unusual entity. Journal of cancer research and therapeutics. 2012 Jul-Sep:8(3):424-6. doi: 10.4103/0973-1482.103524. Epub
[PubMed PMID: 23174726]
[4]
Durfee RA, Mohammed M, Luu HH. Review of Osteosarcoma and Current Management. Rheumatology and therapy. 2016 Dec:3(2):221-243
[PubMed PMID: 27761754]
[5]
Tiwari A. Current concepts in surgical treatment of osteosarcoma. Journal of clinical orthopaedics and trauma. 2012 Jun:3(1):4-9. doi: 10.1016/j.jcot.2012.04.004. Epub 2012 Jun 16
[PubMed PMID: 25983449]
[6]
Taran SJ, Taran R, Malipatil NB. Pediatric Osteosarcoma: An Updated Review. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology. 2017 Jan-Mar:38(1):33-43. doi: 10.4103/0971-5851.203513. Epub
[PubMed PMID: 28469335]
[7]
Nie Z, Peng H. Osteosarcoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes. Oncology letters. 2018 Nov:16(5):6502-6514. doi: 10.3892/ol.2018.9453. Epub 2018 Sep 18
[PubMed PMID: 30405789]
Level 2 (mid-level) evidence
[8]
Lin YH, Jewell BE, Gingold J, Lu L, Zhao R, Wang LL, Lee DF. Osteosarcoma: Molecular Pathogenesis and iPSC Modeling. Trends in molecular medicine. 2017 Aug:23(8):737-755. doi: 10.1016/j.molmed.2017.06.004. Epub 2017 Jul 20
[PubMed PMID: 28735817]
[9]
Lamplot JD, Denduluri S, Qin J, Li R, Liu X, Zhang H, Chen X, Wang N, Pratt A, Shui W, Luo X, Nan G, Deng ZL, Luo J, Haydon RC, He TC, Luu HH. The Current and Future Therapies for Human Osteosarcoma. Current cancer therapy reviews. 2013 Feb:9(1):55-77
[PubMed PMID: 26834515]
Level 2 (mid-level) evidence
[10]
Xu H, Zhan W, Chen Z. Ras-Association Domain Family 1 Isoform A (RASSF1A) Gene Polymorphism rs1989839 is Associated with Risk and Metastatic Potential of Osteosarcoma in Young Chinese Individuals: A Multi-Center, Case-Control Study. Medical science monitor : international medical journal of experimental and clinical research. 2016 Nov 23:22():4529-4535
[PubMed PMID: 27880743]
Level 2 (mid-level) evidence
[11]
Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, DeLuca DS, Lawrence MS, Ambrogio L, Sougnez C, Sivachenko A, Walensky LD, Wagle N, Mora J, de Torres C, Lavarino C, Dos Santos Aguiar S, Yunes JA, Brandalise SR, Mercado-Celis GE, Melendez-Zajgla J, Cárdenas-Cardós R, Velasco-Hidalgo L, Roberts CW, Garraway LA, Rodriguez-Galindo C, Gabriel SB, Lander ES, Golub TR, Orkin SH, Getz G, Janeway KA. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 2014 Dec 23:111(51):E5564-73. doi: 10.1073/pnas.1419260111. Epub 2014 Dec 15
[PubMed PMID: 25512523]
[12]
de Azevedo JWV, de Medeiros Fernandes TAA, Fernandes JV Jr, de Azevedo JCV, Lanza DCF, Bezerra CM, Andrade VS, de Araújo JMG, Fernandes JV. Biology and pathogenesis of human osteosarcoma. Oncology letters. 2020 Feb:19(2):1099-1116. doi: 10.3892/ol.2019.11229. Epub 2019 Dec 18
[PubMed PMID: 31966039]
Level 3 (low-level) evidence
[13]
Yao Z, Han L, Chen Y, He F, Sun B, Kamar S, Zhang Y, Yang Y, Wang C, Yang Z. Hedgehog signalling in the tumourigenesis and metastasis of osteosarcoma, and its potential value in the clinical therapy of osteosarcoma. Cell death & disease. 2018 Jun 13:9(6):701. doi: 10.1038/s41419-018-0647-1. Epub 2018 Jun 13
[PubMed PMID: 29899399]
[14]
Morrow JJ, Khanna C. Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies. Critical reviews in oncogenesis. 2015:20(3-4):173-97
[PubMed PMID: 26349415]
[15]
Tavanti E, Sero V, Vella S, Fanelli M, Michelacci F, Landuzzi L, Magagnoli G, Versteeg R, Picci P, Hattinger CM, Serra M. Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. British journal of cancer. 2013 Nov 12:109(10):2607-18. doi: 10.1038/bjc.2013.643. Epub 2013 Oct 15
[PubMed PMID: 24129234]
Level 1 (high-level) evidence
[16]
Puranik SR, Puranik RS, Ramdurg PK, Choudhary GR. Parosteal osteosarcoma: Report of a rare juxtacortical variant of osteosarcoma affecting the maxilla. Journal of oral and maxillofacial pathology : JOMFP. 2014 Sep-Dec:18(3):432-6. doi: 10.4103/0973-029X.151340. Epub
[PubMed PMID: 25949002]
[17]
Fuchs B, Hoekzema N, Larson DR, Inwards CY, Sim FH. Osteosarcoma of the pelvis: outcome analysis of surgical treatment. Clinical orthopaedics and related research. 2009 Feb:467(2):510-8. doi: 10.1007/s11999-008-0495-x. Epub 2008 Oct 15
[PubMed PMID: 18855090]
[18]
Katonis P, Datsis G, Karantanas A, Kampouroglou A, Lianoudakis S, Licoudis S, Papoutsopoulou E, Alpantaki K. Spinal osteosarcoma. Clinical Medicine Insights. Oncology. 2013 Aug 18:7():199-208. doi: 10.4137/CMO.S10099. Epub 2013 Aug 18
[PubMed PMID: 24179411]
[19]
Chaudhary M, Chaudhary SD. Osteosarcoma of jaws. Journal of oral and maxillofacial pathology : JOMFP. 2012 May:16(2):233-8. doi: 10.4103/0973-029X.99075. Epub
[PubMed PMID: 22923896]
[20]
Cutilli T, Scarsella S, Fabio DD, Oliva A, Cargini P. High-grade chondroblastic and fibroblastic osteosarcoma of the upper jaw. Annals of maxillofacial surgery. 2011 Jul:1(2):176-80. doi: 10.4103/2231-0746.92790. Epub
[PubMed PMID: 23482406]
[21]
Nouri H, Ben Maitigue M, Abid L, Nouri N, Abdelkader A, Bouaziz M, Mestiri M. Surface osteosarcoma: Clinical features and therapeutic implications. Journal of bone oncology. 2015 Dec:4(4):115-23. doi: 10.1016/j.jbo.2015.07.002. Epub 2015 Nov 10
[PubMed PMID: 26730360]
[22]
Kumar VS, Barwar N, Khan SA. Surface osteosarcomas: Diagnosis, treatment and outcome. Indian journal of orthopaedics. 2014 May:48(3):255-61. doi: 10.4103/0019-5413.132503. Epub
[PubMed PMID: 24932030]
[23]
Yang Y, Yang R, Roth M, Piperdi S, Zhang W, Dorfman H, Rao P, Park A, Tripathi S, Freeman C, Zhang Y, Sowers R, Rosenblum J, Geller D, Hoang B, Gill J, Gorlick R. Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model. Genes & cancer. 2017 Jan:8(1-2):484-494. doi: 10.18632/genesandcancer.133. Epub
[PubMed PMID: 28435520]
[24]
Hameed M, Mandelker D. Tumor Syndromes Predisposing to Osteosarcoma. Advances in anatomic pathology. 2018 Jul:25(4):217-222. doi: 10.1097/PAP.0000000000000190. Epub
[PubMed PMID: 29668499]
Level 3 (low-level) evidence
[25]
Sarkar R. Pathological and clinical features of primary osseous tumours of the jaw. Journal of bone oncology. 2014 Nov:3(3-4):90-5. doi: 10.1016/j.jbo.2014.06.001. Epub 2014 Jul 11
[PubMed PMID: 26909304]
[26]
Gonzalez AL, Cates JM. Osteosarcoma: Differential Diagnostic Considerations. Surgical pathology clinics. 2012 Mar:5(1):117-46. doi: 10.1016/j.path.2011.07.011. Epub 2011 Dec 15
[PubMed PMID: 26837918]
[27]
Klein MJ, Siegal GP. Osteosarcoma: anatomic and histologic variants. American journal of clinical pathology. 2006 Apr:125(4):555-81
[PubMed PMID: 16627266]
[28]
Kashikar S, Steinle M, Reich R, Freedman P. Epithelioid Multinodular Osteoblastoma of the Mandible: A Case Report and Review of Literature. Head and neck pathology. 2016 Jun:10(2):182-7. doi: 10.1007/s12105-015-0665-6. Epub 2015 Oct 27
[PubMed PMID: 26507845]
Level 3 (low-level) evidence
[29]
Stitzlein RN, Wojcik J, Sebro RA, Balamuth NJ, Weber KL. Team Approach: Osteosarcoma of the Distal Part of the Femur in Adolescents. JBJS reviews. 2017 Dec:5(12):e5. doi: 10.2106/JBJS.RVW.17.00030. Epub
[PubMed PMID: 29278618]
[30]
McCarville MB, Chen JY, Coleman JL, Li Y, Li X, Adderson EE, Neel MD, Gold RE, Kaufman RA. Distinguishing Osteomyelitis From Ewing Sarcoma on Radiography and MRI. AJR. American journal of roentgenology. 2015 Sep:205(3):640-50; quiz 651. doi: 10.2214/AJR.15.14341. Epub
[PubMed PMID: 26295653]
[31]
Zhou Y, Lu Q, Xu J, Yan R, Zhu J, Xu J, Jiang X, Li J, Wu F. The effect of pathological fractures on the prognosis of patients with osteosarcoma: a meta-analysis of 14 studies. Oncotarget. 2017 Sep 22:8(42):73037-73049. doi: 10.18632/oncotarget.20375. Epub 2017 Aug 21
[PubMed PMID: 29069847]
Level 1 (high-level) evidence
[32]
Ong ZY, Chai HZ, How CH, Koh J, Low TB. A simplified approach to haemoptysis. Singapore medical journal. 2016 Aug:57(8):415-8. doi: 10.11622/smedj.2016130. Epub
[PubMed PMID: 27549136]
[33]
Feng D, Yang X, Liu T, Xiao J, Wu Z, Huang Q, Ma J, Huang W, Zheng W, Cui Z, Xu H, Teng Y. Osteosarcoma of the spine: surgical treatment and outcomes. World journal of surgical oncology. 2013 Apr 18:11(1):89. doi: 10.1186/1477-7819-11-89. Epub 2013 Apr 18
[PubMed PMID: 23597053]
[34]
Choi D, Crockard A, Bunger C, Harms J, Kawahara N, Mazel C, Melcher R, Tomita K, Global Spine Tumor Study Group. Review of metastatic spine tumour classification and indications for surgery: the consensus statement of the Global Spine Tumour Study Group. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2010 Feb:19(2):215-22. doi: 10.1007/s00586-009-1252-x. Epub 2009 Dec 29
[PubMed PMID: 20039084]
Level 3 (low-level) evidence
[35]
Frezza AM, Beale T, Bomanji J, Jay A, Kalavrezos N, Dileo P, Whelan J, Strauss SJ. Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment? BMC cancer. 2014 Jan 15:14():23. doi: 10.1186/1471-2407-14-23. Epub 2014 Jan 15
[PubMed PMID: 24422949]
[36]
Nascimento D, Suchard G, Hatem M, de Abreu A. The role of magnetic resonance imaging in the evaluation of bone tumours and tumour-like lesions. Insights into imaging. 2014 Aug:5(4):419-40. doi: 10.1007/s13244-014-0339-z. Epub 2014 Jul 9
[PubMed PMID: 25005774]
[37]
Nthumba PM. Osteosarcoma of the jaws: a review of literature and a case report on synchronous multicentric osteosarcomas. World journal of surgical oncology. 2012 Nov 12:10():240. doi: 10.1186/1477-7819-10-240. Epub 2012 Nov 12
[PubMed PMID: 23140538]
Level 3 (low-level) evidence
[38]
Fernandes GL, Natal MRC, da Cruz CLP, Nascif RL, Tsuno NSG, Tsuno MY. Primary osteosarcoma of the cranial vault. Radiologia brasileira. 2017 Jul-Aug:50(4):263-265. doi: 10.1590/0100-3984.1914-2014. Epub
[PubMed PMID: 28894335]
[39]
Kundu ZS. Classification, imaging, biopsy and staging of osteosarcoma. Indian journal of orthopaedics. 2014 May:48(3):238-46. doi: 10.4103/0019-5413.132491. Epub
[PubMed PMID: 24932027]
[40]
Sun Y, Liu X, Pan S, Deng C, Li X, Guo Q. Analysis of imaging characteristics of primary malignant bone tumors in children. Oncology letters. 2017 Nov:14(5):5801-5810. doi: 10.3892/ol.2017.6939. Epub 2017 Sep 14
[PubMed PMID: 29113210]
Level 3 (low-level) evidence
[41]
Gerrand C, Athanasou N, Brennan B, Grimer R, Judson I, Morland B, Peake D, Seddon B, Whelan J, British Sarcoma Group. UK guidelines for the management of bone sarcomas. Clinical sarcoma research. 2016:6():7. doi: 10.1186/s13569-016-0047-1. Epub 2016 May 4
[PubMed PMID: 27148438]
[42]
Li X, Seebacher NA, Hornicek FJ, Xiao T, Duan Z. Application of liquid biopsy in bone and soft tissue sarcomas: Present and future. Cancer letters. 2018 Dec 28:439():66-77. doi: 10.1016/j.canlet.2018.09.012. Epub 2018 Sep 14
[PubMed PMID: 30223067]
Level 3 (low-level) evidence
[43]
Baguley DM, Prayuenyong P. Looking beyond the audiogram in ototoxicity associated with platinum-based chemotherapy. Cancer chemotherapy and pharmacology. 2020 Feb:85(2):245-250. doi: 10.1007/s00280-019-04012-z. Epub 2019 Dec 21
[PubMed PMID: 31865419]
[44]
Ando K, Heymann MF, Stresing V, Mori K, Rédini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers. 2013 May 24:5(2):591-616. doi: 10.3390/cancers5020591. Epub 2013 May 24
[PubMed PMID: 24216993]
[45]
Bielack SS, Hecker-Nolting S, Blattmann C, Kager L. Advances in the management of osteosarcoma. F1000Research. 2016:5():2767
[PubMed PMID: 27990273]
Level 3 (low-level) evidence
[46]
Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT-J. 2018:4():12. doi: 10.1051/sicotj/2017028. Epub 2018 Apr 9
[PubMed PMID: 29629690]
[47]
Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Budd GT, Curry WT, Didwania A, Fabbri N, Hornicek FJ, Kuechle JB, Lindskog D, Mayerson J, McGarry SV, Million L, Morris CD, Movva S, O'Donnell RJ, Randall RL, Rose P, Santana VM, Satcher RL, Schwartz H, Siegel HJ, Thornton K, Villalobos V, Bergman MA, Scavone JL. NCCN Guidelines Insights: Bone Cancer, Version 2.2017. Journal of the National Comprehensive Cancer Network : JNCCN. 2017 Feb:15(2):155-167
[PubMed PMID: 28188186]
[48]
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY, ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1:29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310. Epub
[PubMed PMID: 30285218]
Level 1 (high-level) evidence
[49]
Li X, Ashana AO, Moretti VM, Lackman RD. The relation of tumour necrosis and survival in patients with osteosarcoma. International orthopaedics. 2011 Dec:35(12):1847-53. doi: 10.1007/s00264-011-1209-7. Epub 2011 Feb 26
[PubMed PMID: 21359502]
[50]
Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Archives of pathology & laboratory medicine. 1977 Jan:101(1):14-8
[PubMed PMID: 299812]
[51]
Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979 Jun:43(6):2163-77
[PubMed PMID: 88251]
[52]
Shepperd S, Gonçalves-Bradley DC, Straus SE, Wee B. Hospital at home: home-based end-of-life care. The Cochrane database of systematic reviews. 2016 Feb 18:2(2):CD009231. doi: 10.1002/14651858.CD009231.pub2. Epub 2016 Feb 18
[PubMed PMID: 26887902]
Level 1 (high-level) evidence
[53]
Barnes H, McDonald J, Smallwood N, Manser R. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. The Cochrane database of systematic reviews. 2016 Mar 31:3(3):CD011008. doi: 10.1002/14651858.CD011008.pub2. Epub 2016 Mar 31
[PubMed PMID: 27030166]
Level 1 (high-level) evidence
[54]
Bertrand TE, Cruz A, Binitie O, Cheong D, Letson GD. Do Surgical Margins Affect Local Recurrence and Survival in Extremity, Nonmetastatic, High-grade Osteosarcoma? Clinical orthopaedics and related research. 2016 Mar:474(3):677-83. doi: 10.1007/s11999-015-4359-x. Epub
[PubMed PMID: 26013153]
[55]
Salzer M, Knahr K, Kotz R, Kristen H. Treatment of osteosarcomata of the distal femur by rotation-plasty. Archives of orthopaedic and traumatic surgery. Archiv fur orthopadische und Unfall-Chirurgie. 1981:99(2):131-6
[PubMed PMID: 6947721]
[56]
Gupta SK, Alassaf N, Harrop AR, Kiefer GN. Principles of rotationplasty. The Journal of the American Academy of Orthopaedic Surgeons. 2012 Oct:20(10):657-67. doi: 10.5435/JAAOS-20-10-657. Epub
[PubMed PMID: 23027695]
[57]
O'Donnell RJ. Compressive osseointegration of tibial implants in primary cancer reconstruction. Clinical orthopaedics and related research. 2009 Nov:467(11):2807-12. doi: 10.1007/s11999-009-0986-4. Epub 2009 Aug 4
[PubMed PMID: 19653050]
[58]
Böhler C, Brönimann S, Kaider A, Puchner SE, Sigmund IK, Windhager R, Funovics PT. Surgical and Functional Outcome after Endoprosthetic Reconstruction in Patients with Osteosarcoma of the Humerus. Scientific reports. 2018 Nov 8:8(1):16148. doi: 10.1038/s41598-018-34397-5. Epub 2018 Nov 8
[PubMed PMID: 30410099]
[59]
Xu L, Zhou J, Wang Z, Xiong J, Qiu Y, Wang S. Reconstruction of bone defect with allograft and retrograde intramedullary nail for distal tibia osteosarcoma. Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons. 2018 Apr:24(2):149-153. doi: 10.1016/j.fas.2017.01.006. Epub 2017 Feb 4
[PubMed PMID: 29409222]
Level 2 (mid-level) evidence
[60]
Sharma DN, Rastogi S, Bakhshi S, Rath GK, Julka PK, Laviraj MA, Khan SA, Kumar A. Role of extracorporeal irradiation in malignant bone tumors. Indian journal of cancer. 2013 Oct-Dec:50(4):306-9. doi: 10.4103/0019-509X.123601. Epub
[PubMed PMID: 24369205]
[61]
Hong A, Stevens G, Stalley P, Pendlebury S, Ahern V, Ralston A, Estoesta E, Barrett I. Extracorporeal irradiation for malignant bone tumors. International journal of radiation oncology, biology, physics. 2001 Jun 1:50(2):441-7
[PubMed PMID: 11380232]
[62]
Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S. The role of radiotherapy in oseosarcoma. Cancer treatment and research. 2009:152():147-64. doi: 10.1007/978-1-4419-0284-9_7. Epub
[PubMed PMID: 20213389]
[63]
Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. The Lancet. Oncology. 2016 Oct:17(10):1396-1408. doi: 10.1016/S1470-2045(16)30214-5. Epub 2016 Aug 25
[PubMed PMID: 27569442]
Level 1 (high-level) evidence
[64]
Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European journal of cancer (Oxford, England : 1990). 2019 Mar:109():36-50. doi: 10.1016/j.ejca.2018.11.027. Epub 2019 Jan 25
[PubMed PMID: 30685685]
[65]
Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, Conrad EU 3rd, Nieder ML, Weiner MA, Wells RJ, Womer RB, Meyers PA, Children's Oncology Group. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009 Nov 15:115(22):5339-48. doi: 10.1002/cncr.24566. Epub
[PubMed PMID: 19637348]
[66]
Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE, Children's Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1:26(4):633-8. doi: 10.1200/JCO.2008.14.0095. Epub
[PubMed PMID: 18235123]
[67]
Jaffe N, Puri A, Gelderblom H. Osteosarcoma: evolution of treatment paradigms. Sarcoma. 2013:2013():203531. doi: 10.1155/2013/203531. Epub 2013 May 27
[PubMed PMID: 23781130]
[68]
O'Kane GM, Cadoo KA, Walsh EM, Emerson R, Dervan P, O'Keane C, Hurson B, O'Toole G, Dudeney S, Kavanagh E, Eustace S, Carney DN. Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review. Clinical sarcoma research. 2015:5():17. doi: 10.1186/s13569-015-0032-0. Epub 2015 Jul 14
[PubMed PMID: 26175892]
[69]
Bacci G, Forni C, Ferrari S, Longhi A, Bertoni F, Mercuri M, Donati D, Capanna R, Bernini G, Briccoli A, Setola E, Versari M. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. Journal of pediatric hematology/oncology. 2003 Nov:25(11):845-53
[PubMed PMID: 14608193]
[70]
Wu C, Wang Q, Li Y. Prediction and evaluation of neoadjuvant chemotherapy using the dual mechanisms of (99m)Tc-MIBI scintigraphy in patients with osteosarcoma. Journal of bone oncology. 2019 Aug:17():100250. doi: 10.1016/j.jbo.2019.100250. Epub 2019 Jul 9
[PubMed PMID: 31372331]
[71]
Benjamin RS, Wagner MJ, Livingston JA, Ravi V, Patel SR. Chemotherapy for bone sarcomas in adults: the MD anderson experience. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015:():e656-60. doi: 10.14694/EdBook_AM.2015.35.e656. Epub
[PubMed PMID: 25993237]
[72]
Niu XH. [Updates and interpretations of 2017 NCCN guidelines for bone cancer]. Zhonghua wai ke za zhi [Chinese journal of surgery]. 2017 Jan 1:55(1):41-43. doi: 10.3760/cma.j.issn.0529-5815.2017.01.011. Epub
[PubMed PMID: 28056253]
[73]
Xiao X, Wang W, Wang Z. The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma. Paediatric drugs. 2014 Dec:16(6):503-12. doi: 10.1007/s40272-014-0095-z. Epub
[PubMed PMID: 25392156]
[74]
Raciborska A, Bilska K. Sorafenib in patients with progressed and refractory bone tumors. Medical oncology (Northwood, London, England). 2018 Aug 16:35(10):126. doi: 10.1007/s12032-018-1180-x. Epub 2018 Aug 16
[PubMed PMID: 30116912]
[75]
Coventon J. A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma. Journal of bone oncology. 2017 Sep:8():4-7. doi: 10.1016/j.jbo.2017.07.001. Epub 2017 Aug 4
[PubMed PMID: 28828294]
[76]
Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, Casali PG, Picci P, Ferrari S, Aglietta M, Italian Sarcoma Group. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. The Lancet. Oncology. 2015 Jan:16(1):98-107. doi: 10.1016/S1470-2045(14)71136-2. Epub 2014 Dec 11
[PubMed PMID: 25498219]
Level 2 (mid-level) evidence
[77]
Rodríguez-Galindo C, Daw NC, Kaste SC, Meyer WH, Dome JS, Pappo AS, Rao BN, Pratt CB. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. Journal of pediatric hematology/oncology. 2002 May:24(4):250-5
[PubMed PMID: 11972091]
[78]
Longo J, Lutz S, Johnstone C. Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases. Cancer management and research. 2013:5():235-42. doi: 10.2147/CMAR.S35789. Epub 2013 Aug 13
[PubMed PMID: 23976864]
[79]
Huang X, Zhao J, Bai J, Shen H, Zhang B, Deng L, Sun C, Liu Y, Zhang J, Zheng J. Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study. Journal of bone oncology. 2019 Jun:16():100230. doi: 10.1016/j.jbo.2019.100230. Epub 2019 Mar 7
[PubMed PMID: 30923668]
[80]
Zhang Y, Yang J, Zhao N, Wang C, Kamar S, Zhou Y, He Z, Yang J, Sun B, Shi X, Han L, Yang Z. Progress in the chemotherapeutic treatment of osteosarcoma. Oncology letters. 2018 Nov:16(5):6228-6237. doi: 10.3892/ol.2018.9434. Epub 2018 Sep 12
[PubMed PMID: 30405759]
Level 3 (low-level) evidence
[81]
Loeb DM, Garrett-Mayer E, Hobbs RF, Prideaux AR, Sgouros G, Shokek O, Wharam MD Jr, Scott T, Schwartz CL. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009 Jun 1:115(11):2514-22. doi: 10.1002/cncr.24286. Epub
[PubMed PMID: 19338063]
[82]
Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: Where do we go from here? Pediatric blood & cancer. 2018 Sep:65(9):e27227. doi: 10.1002/pbc.27227. Epub 2018 Jun 19
[PubMed PMID: 29923370]
[83]
Salmen J, Banys-Paluchowski M, Fehm T. Bone-Targeted Therapy. Geburtshilfe und Frauenheilkunde. 2015 Jun:75(6):584-587
[PubMed PMID: 26166839]
[84]
Farrell KB, Karpeisky A, Thamm DH, Zinnen S. Bisphosphonate conjugation for bone specific drug targeting. Bone reports. 2018 Dec:9():47-60. doi: 10.1016/j.bonr.2018.06.007. Epub 2018 Jul 3
[PubMed PMID: 29992180]
[85]
Li X, Moretti VM, Ashana AO, Lackman RD. Impact of close surgical margin on local recurrence and survival in osteosarcoma. International orthopaedics. 2012 Jan:36(1):131-7. doi: 10.1007/s00264-011-1230-x. Epub 2011 Mar 15
[PubMed PMID: 21404025]
[86]
Bispo Júnior RZ, Camargo OP. Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy. Clinics (Sao Paulo, Brazil). 2009:64(12):1177-86. doi: 10.1590/S1807-59322009001200007. Epub
[PubMed PMID: 20037705]
[87]
Wadhwa N. Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors. Indian journal of orthopaedics. 2014 May:48(3):247-54. doi: 10.4103/0019-5413.132497. Epub
[PubMed PMID: 24932029]
[88]
Zumárraga JP, Baptista AM, Rosa LP, Caiero MT, Camargo OP. SERUM VALUES OF ALKALINE PHOSPHATASE AND LACTATE DEHYDROGENASE IN OSTEOSARCOMA. Acta ortopedica brasileira. 2016 May-Jun:24(3):142-6. doi: 10.1590/1413-785220162403157033. Epub
[PubMed PMID: 27217815]
[89]
Horvai A, Unni KK. Premalignant conditions of bone. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association. 2006 Jul:11(4):412-23
[PubMed PMID: 16897210]
[90]
Unni KK. Osteosarcoma of bone. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association. 1998:3(5):287-94
[PubMed PMID: 9732564]
[91]
Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. International orthopaedics. 2006 Dec:30(6):445-51
[PubMed PMID: 16896870]
[92]
McHugh JB, Thomas DG, Herman JM, Ray ME, Baker LH, Adsay NV, Rabah R, Lucas DR. Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons. Cancer. 2006 Aug 1:107(3):554-62
[PubMed PMID: 16795069]
[93]
Yang Q, Chen T, Yao Z, Zhang X. Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma. World journal of surgical oncology. 2020 Jan 30:18(1):24. doi: 10.1186/s12957-020-1789-z. Epub 2020 Jan 30
[PubMed PMID: 32000789]
[94]
Jettoo P, Tan G, Gerrand CH, Rankin KS. Role of routine blood tests for predicting clinical outcomes in osteosarcoma patients. Journal of orthopaedic surgery (Hong Kong). 2019 May-Aug:27(2):2309499019838293. doi: 10.1177/2309499019838293. Epub
[PubMed PMID: 30909848]
Level 2 (mid-level) evidence
[95]
Jawad MU, Scully SP. In brief: classifications in brief: Mirels' classification: metastatic disease in long bones and impending pathologic fracture. Clinical orthopaedics and related research. 2010 Oct:468(10):2825-7. doi: 10.1007/s11999-010-1326-4. Epub
[PubMed PMID: 20352387]
[96]
Ormsby NM, Leong WY, Wong W, Hughes HE, Swaminathan V. The current status of prophylactic femoral intramedullary nailing for metastatic cancer. Ecancermedicalscience. 2016:10():698. doi: 10.3332/ecancer.2016.698. Epub 2016 Dec 1
[PubMed PMID: 28105069]
[97]
Saumet L, Deschamps F, Marec-Berard P, Gaspar N, Corradini N, Petit P, Sirvent N, Brugières L. Radiofrequency ablation of metastases from osteosarcoma in patients under 25 years: the SCFE experience. Pediatric hematology and oncology. 2015 Feb:32(1):41-9. doi: 10.3109/08880018.2014.926469. Epub 2014 Jul 9
[PubMed PMID: 25007012]
[98]
Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathologic fracture in osteosarcoma : prognostic importance and treatment implications. The Journal of bone and joint surgery. American volume. 2002 Jan:84(1):49-57
[PubMed PMID: 11792779]
[99]
Pflugmacher R, Beth P, Schroeder RJ, Schaser KD, Melcher I. Balloon kyphoplasty for the treatment of pathological fractures in the thoracic and lumbar spine caused by metastasis: one-year follow-up. Acta radiologica (Stockholm, Sweden : 1987). 2007 Feb:48(1):89-95
[PubMed PMID: 17325932]
[101]
Ng AK, Kenney LB, Gilbert ES, Travis LB. Secondary malignancies across the age spectrum. Seminars in radiation oncology. 2010 Jan:20(1):67-78. doi: 10.1016/j.semradonc.2009.09.002. Epub
[PubMed PMID: 19959033]
[102]
Zhou W, Hao M, Du X, Chen K, Wang G, Yang J. Advances in targeted therapy for osteosarcoma. Discovery medicine. 2014 Jun:17(96):301-7
[PubMed PMID: 24979249]
Level 3 (low-level) evidence
[103]
Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, González MV, Baldini N, Garcia-Castro J, Rodriguez R. Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem cells international. 2016:2016():3631764. doi: 10.1155/2016/3631764. Epub 2016 Jun 5
[PubMed PMID: 27366153]
[104]
Ayerza MA, Farfalli GL, Aponte-Tinao L, Muscolo DL. Does increased rate of limb-sparing surgery affect survival in osteosarcoma? Clinical orthopaedics and related research. 2010 Nov:468(11):2854-9. doi: 10.1007/s11999-010-1423-4. Epub
[PubMed PMID: 20559766]
[105]
Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS, Shinohara ET, Bridge JA, Loeb DM, Borinstein SC, Isakoff MS. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 2017 Jun 15:123(12):2206-2218. doi: 10.1002/cncr.30589. Epub 2017 Mar 21
[PubMed PMID: 28323337]
[106]
Andritsch E, Beishon M, Bielack S, Bonvalot S, Casali P, Crul M, Delgado Bolton R, Donati DM, Douis H, Haas R, Hogendoorn P, Kozhaeva O, Lavender V, Lovey J, Negrouk A, Pereira P, Roca P, de Lempdes GR, Saarto T, van Berck B, Vassal G, Wartenberg M, Yared W, Costa A, Naredi P. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. Critical reviews in oncology/hematology. 2017 Feb:110():94-105. doi: 10.1016/j.critrevonc.2016.12.002. Epub 2016 Dec 8
[PubMed PMID: 28109409]
Level 2 (mid-level) evidence